LABS vs. HLS, RX, TGOD, NINE, WMD, MDP, VIR, CWEB, ZOM, and IN
Should you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include HLS Therapeutics (HLS), BioSyent (RX), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), WeedMD (WMD), Medexus Pharmaceuticals (MDP), Viridium Pacific Group (VIR), Charlotte's Web (CWEB), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), and InMed Pharmaceuticals (IN). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics (TSE:HLS) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
In the previous week, HLS Therapeutics had 2 more articles in the media than MediPharm Labs. MarketBeat recorded 2 mentions for HLS Therapeutics and 0 mentions for MediPharm Labs. MediPharm Labs' average media sentiment score of 1.19 beat HLS Therapeutics' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.
HLS Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, MediPharm Labs has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
59.7% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of MediPharm Labs shares are owned by institutional investors. 0.5% of HLS Therapeutics shares are owned by insiders. Comparatively, 2.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MediPharm Labs has a net margin of -39.57% compared to MediPharm Labs' net margin of -45.81%. HLS Therapeutics' return on equity of -24.00% beat MediPharm Labs' return on equity.
MediPharm Labs has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.
HLS Therapeutics presently has a consensus target price of C$3.88, indicating a potential upside of 4.17%. Given MediPharm Labs' higher possible upside, research analysts plainly believe HLS Therapeutics is more favorable than MediPharm Labs.
HLS Therapeutics received 9 more outperform votes than MediPharm Labs when rated by MarketBeat users. Likewise, 68.00% of users gave HLS Therapeutics an outperform vote while only 65.79% of users gave MediPharm Labs an outperform vote.
Summary
HLS Therapeutics beats MediPharm Labs on 11 of the 17 factors compared between the two stocks.
Get MediPharm Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediPharm Labs Competitors List
Related Companies and Tools
